Gepotidacin - GlaxoSmithKline

Drug Profile

Gepotidacin - GlaxoSmithKline

Alternative Names: 2140944; GSK 2140944; GSK-2140944E

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Acenaphthenes; Antibacterials; Aza compounds; Ketones; Piperidines; Pyridines; Pyrones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gonorrhoea; Skin and soft tissue infections
  • Phase I Bacterial infections
  • No development reported Respiratory tract infections

Most Recent Events

  • 26 Jun 2018 GlaxoSmithKline in collaboration with Biomedical Advanced Research and Development Authority plans a phase I pharmacokinetic trial in hepatic impairment patients in USA (PO, Tablet) (NCT03562117)
  • 11 Jun 2018 GlaxoSmithKline in collaboration with Biomedical Advanced Research and Development Authority initiates enrolment in a phase I pharmacokinetic trial in hepatic impairment patients in USA (PO, Tablet) (NCT03562117)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-tract-infections(In volunteers) in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top